Clinical Trials
Clinilabs Strengthens Leadership Team to Drive CNS Drug Development Growth
Clinilabs, LLC enhances its executive team with the appointment of David Hagerman as CFO and Jeanine Falinski as SVP of Commercial Development, signaling a strategic push to bolster its position in CNS drug and medical technology development.
NanoViricides Advances Measles Drug Program as Global Outbreaks Rise
NanoViricides, Inc. has begun animal trials for its antiviral candidate NV-387, targeting measles amidst increasing global outbreaks and vaccine challenges, highlighting a critical step towards addressing a significant public health gap.
Understanding Pediatric Growth Hormone Deficiency: Impacts and Advances in Treatment
Pediatric Growth Hormone Deficiency (PGHD) affects 1 in 4,000-10,000 children, influencing their growth, development, and overall health, with early diagnosis and treatment offering a path to improved outcomes.
Soligenix Inc. (SNGX) Reports Promising HyBryte Results for CTCL Treatment
Interim data from a Soligenix Inc. study highlights HyBryte's potential as a safer, faster-acting treatment for cutaneous T-cell lymphoma, offering new hope for patients with this chronic condition.
GeoVax to Present COVID-19 Vaccine Breakthroughs at Keystone Symposia
GeoVax Labs, Inc. will showcase data from two key studies at the Keystone Symposia, highlighting the cross-reactivity and broad-spectrum immunity of its COVID-19 vaccine candidates, marking a significant step forward in the fight against evolving SARS-CoV-2 variants.
Alzamend Neuro Launches Phase II Trial for Innovative Lithium-Based Alzheimer's Therapy
Alzamend Neuro has initiated a Phase II clinical trial for AL001, a novel lithium therapy targeting multiple neuropsychiatric conditions, with potential to improve brain drug delivery and reduce side effects.
Breakthrough Stem Cell Dog Chews Show Promising Results in Veterinary Trials
Bioadaptives Inc's PawPa division has developed Regen Dog Chews that demonstrate significant potential for improving canine health through natural stem cell stimulation, with clinical trials showing a dramatic increase in circulating stem cells.
Quantum BioPharma Advances Clinical Trial for MCAS Pain Treatment
Quantum BioPharma has received Australian ethics approval for a Phase 2 clinical trial of FSD202, a potential treatment for chronic pain associated with Mast Cell Activation Syndrome (MCAS), signaling progress in addressing a challenging medical condition.
FDA Updates COVID-19 Vaccination Strategy, GeoVax Poised to Meet Targeted Needs
The FDA has shifted to a risk-based COVID-19 vaccination approach, prioritizing protection for vulnerable populations. GeoVax's multi-antigen vaccine GEO-CM04S1 appears well-positioned to address these evolving public health requirements.
American Heart Association Launches Initiative to Improve Clinical Trial Access for Rare Heart Condition
The American Heart Association is addressing healthcare disparities by launching a comprehensive initiative to improve education, outreach, and access to clinical trials for transthyretin amyloid cardiomyopathy (ATTR-CM), focusing on underrepresented populations and emerging gene editing therapies.
Beam Therapeutics to Unveil Promising Sickle Cell Disease Treatment Data at European Hematology Congress
Beam Therapeutics will present updated results from its BEACON trial for BEAM-101, an innovative ex vivo cell therapy targeting sickle cell disease, highlighting potential breakthrough treatment approaches at the European Hematology Association 2025 Congress.
Beam Therapeutics to Present Breakthrough Sickle Cell Disease Data at European Hematology Congress
Beam Therapeutics will reveal updated results from its BEACON trial on BEAM-101, an innovative ex vivo cell therapy targeting severe sickle cell disease, highlighting potential advances in genetic medicine treatment strategies.
Soligenix's HyBryte Shows Promising Results in Rare Cancer Treatment
Soligenix reports significant progress in treating cutaneous T-cell lymphoma (CTCL) with its experimental therapy HyBryte, demonstrating 75% treatment success after 18 weeks of clinical trials. The breakthrough offers potential hope for patients with this challenging rare skin cancer.
Tonix Pharmaceuticals CEO Highlights Strategic Developments at A.G.P. Healthcare Showcase
Tonix Pharmaceuticals CEO Seth Lederman shared key strategic insights during a fireside chat, emphasizing the company's integrated business model and advanced clinical pipeline, with particular focus on potential treatments for fibromyalgia and potential defense-related medical innovations.
Tonix Pharmaceuticals Launches Phase 2 Trial for Acute Stress Reaction Treatment
Tonix Pharmaceuticals has initiated a Department of Defense-backed clinical trial to evaluate TNX-102 SL as a potential treatment for acute stress reaction in motor vehicle trauma survivors, addressing a critical need in mental health care.
New Study Validates PREVENT Risk Calculator for Heart Attack Prediction
A study of nearly 7,000 adults demonstrates the accuracy of the American Heart Association's PREVENT risk calculator in identifying individuals with potential heart disease risk, using coronary calcium scores as a complementary screening tool.
Quantum BioPharma Advances Multiple Sclerosis Drug Toward Clinical Trials
Quantum BioPharma has signed an agreement with a contract research organization to prepare an Investigational New Drug application for Lucid-21-302, a potential breakthrough therapy for multiple sclerosis that could prevent neurological damage.
American Heart Association Awards $1.2 Million in Food as Medicine Research Grants
The American Heart Association has awarded $1.2 million in planning grants to 12 scientific researchers to develop clinical trial protocols exploring food intervention strategies for chronic disease management. These grants aim to test approaches that could transform healthcare delivery and potentially reduce diet-related medical costs.
GeoVax Develops Multi-Antigen COVID-19 Vaccine Targeting Immunocompromised Populations
GeoVax's innovative GEO-CM04S1 vaccine addresses critical gaps in COVID-19 immunization strategies by offering broad, durable protection for vulnerable populations as HHS shifts towards risk-based vaccine recommendations.
CNS Pharmaceuticals Advances Brain Cancer Treatment, Reports Q1 Financial Results
CNS Pharmaceuticals is progressing its brain cancer treatment TPI 287, with increased R&D spending and plans for a Phase 2 study in recurrent glioblastoma multiforme, while maintaining financial runway into 2026.
NanoViricides Advances Broad-Spectrum Antiviral Drug, Eyes Multiple Phase II Trials
NanoViricides is progressing its NV-387 drug candidate across multiple viral infections, with pending Phase II trials for MPox and emerging programs for measles and avian flu, highlighting significant potential in antiviral treatment development.
Soligenix Advances Phase 3 Trial for Cutaneous T-Cell Lymphoma Treatment, Zacks Report Shows Promise
Soligenix continues enrollment in its Phase 3 HyBryte trial for cutaneous T-cell lymphoma, with Zacks Research highlighting the trial's high potential for success and anticipated topline results in 2026.
Calidi Biotherapeutics Advances Cancer Immunotherapy Platform, Reduces Quarterly Losses
Calidi Biotherapeutics has made significant progress in its oncology research, receiving FDA clearance for a stem cell-based immunotherapy and presenting promising data on its Redtail virotherapy platform while simultaneously reducing operational expenses.
New Study Suggests Combining Fluoride and Iodine Could Enhance Cavity Prevention
A recent study reveals that using fluoride and iodine together may significantly reduce tooth decay in children, potentially offering a more effective approach to dental care than fluoride treatment alone.
Silo Pharma Advances PTSD Treatment with FDA-Requested Safety Study
Silo Pharma is conducting a critical safety study on its intranasal PTSD treatment SPC-15, which could potentially provide a new therapeutic option for patients struggling with stress-related disorders by meeting FDA requirements for clinical advancement.
Annovis Bio Advances Alzheimer's Treatment with Phase 3 Clinical Trial
Annovis Bio has initiated a pivotal Phase 3 clinical trial for buntanetap, a potential treatment for early Alzheimer's disease, with the potential to address symptomatic and disease-modifying aspects of the condition.
SeaStar Medical Achieves Six FDA Breakthrough Device Designations, Promising New Hope for Critical Care Patients
SeaStar Medical has secured six FDA Breakthrough Device Designations for its Selective Cytopheretic Device (SCD) therapy, targeting life-threatening conditions with limited treatment options. These designations highlight the potential to transform care for patients with acute kidney injury, inflammatory responses, and other critical health challenges.
Oragenics Receives Australian Approval for Phase II Concussion Trial
Biotechnology company Oragenics has secured regulatory approval to launch a Phase II clinical trial for ONP-002, a novel intranasal therapy targeting mild traumatic brain injury. The trial represents a potential advancement in treating concussions with a non-invasive approach.
CNS Pharmaceuticals Secures Orphan Drug Designation for Brain Cancer Treatment
CNS Pharmaceuticals has transferred Orphan Drug Designation for TPI 287, a promising microtubule-stabilizing drug targeting brain cancer and neurological conditions. The designation could provide significant market advantages and potential treatment options for patients with challenging neurological disorders.
Tonix Pharmaceuticals Advances Fibromyalgia Drug, Reports Q1 Financial Results
Tonix Pharmaceuticals is poised for potential FDA approval of TNX-102 SL, a novel non-opioid fibromyalgia treatment, while maintaining a robust research pipeline and strong cash position. The drug could represent a significant breakthrough in fibromyalgia treatment after more than 15 years without a new drug class.